Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN

Leukemia. 2020 Apr;34(4):1197-1201. doi: 10.1038/s41375-019-0620-8. Epub 2019 Nov 12.

Authors

Affiliations

¹ Celgene Corporation, Summit, NJ, USA.
² Celgene Corporation, San Diego, CA, USA.
³ Celgene Corporation, CITRE, Sevilla, Spain.
⁴ Celgene Corporation, Summit, NJ, USA. athakurta@celgene.com.

No abstract available

Publication types

Letter

MeSH terms

Adaptor Proteins, Signal Transducing / antagonists & inhibitors
Adaptor Proteins, Signal Transducing / genetics
Adaptor Proteins, Signal Transducing / immunology
Adaptor Proteins, Signal Transducing / metabolism*
Antineoplastic Combined Chemotherapy Protocols / pharmacology*
Clinical Trials as Topic
Drug Resistance, Neoplasm / drug effects*
Heterocyclic Compounds, 4 or More Rings / administration & dosage
Humans
Lenalidomide / administration & dosage
Leukocytes, Mononuclear / drug effects*
Leukocytes, Mononuclear / pathology
Morpholines
Multiple Myeloma / drug therapy*
Multiple Myeloma / immunology
Multiple Myeloma / metabolism
Multiple Myeloma / pathology
Phthalimides
Piperidones
Thalidomide / administration & dosage
Thalidomide / analogs & derivatives
Tumor Cells, Cultured
Ubiquitin-Protein Ligases

Substances

Adaptor Proteins, Signal Transducing
CRBN protein, human
Heterocyclic Compounds, 4 or More Rings
Morpholines
Phthalimides
Piperidones
Thalidomide
iberdomide
pomalidomide
Ubiquitin-Protein Ligases
Lenalidomide